Class of Stock [Axis]
Series A Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Cash and Cash Equivalents [Axis]
Money Market Funds [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Research Collaboration, License and Patent Assignment Agreement [Member]
Altanispac Agreement [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Long-Lived Asset, Class [Axis]
Office Equipment [Member]
Equipment [Member]
Leasehold Improvements [Member]
Warrant [Member]
Segments [Axis]
Single Reportable Segment [Member]
Convertible Series D Preferred Stocks [Member]
Sale of Stock [Axis]
June 2025 Private Placement [Member]
Convertible Series A Preferred Stocks [Member]
Related and Nonrelated Parties [Axis]
Alliance Global Partners [Member]
Plan Name [Axis]
November 2025 PreFunded Warrants [Member]
November 2025 Series J Warrants [Member]
November 2025 Series K Warrants [Member]
Series K Warrants [Member]
May 2025 Series F Warrants [Member]
Investors [Member]
May 2025 Series G Warrants [Member]
May 2025 Series H Warrants [Member]
February 2025 Series E Warrants [Member]
Private Placement [Member]
Class of Warrant or Right [Axis]
Series G Warrants [Member]
Series H Warrants [Member]
Stock Warrants [Member]
December 2024 Existing Warrants [Member]
Series C Warrants [Member]
Series D Warrants [Member]
2011 Stock Incentive Plan [Member]
Time Based Stock Options [Member]
Performance Based Stock Options [Member]
Title and Position [Axis]
Executive Officers [Member]
Other Employees [Member]
Time Based Restricted Stock Units [Member]
Executive Officer [Member]
Performance Based Restricted Stock Units [Member]
Series F Warrants [Member]
Series J Warrants [Member]
October 2022 Placement Agent Warrants [Member]
October 2023 Placement Agent Warrants [Member]
January 2024 Private Warrants [Member]
January 2024 Placement Agent Warrants [Member]
June 2024 Series B Warrants [Member]
December 2024 Series C Warrants [Member]
December 2024 Series D Warrants [Member]
June 2025 Series I Warrants [Member]
November 2025 Placement Agent Warrants [Member]
November 2025 HCW Settlement Warrants [Member]
Income Tax Authority, Name [Axis]
State [Member]
Internal Revenue Service (IRS) [Member]
Income Tax Jurisdiction, Foreign [Member]
Income Tax Jurisdiction [Axis]
Income Tax Jurisdiction, Domestic Federal [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Auditor Opinion [Text Block]
Auditor Name
Auditor Location
Auditor Firm ID
Statement [Table]
Statement [Line Items]
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable
Other receivables
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Right-of-use assets - operating leases
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)
Current liabilities:
Accounts payable
Accrued expenses
Short-term operating lease liabilities
Total current liabilities
Long-term operating lease liabilities
Total liabilities
Commitments and contingencies (Note 12)
Stockholders’ equity (deficiency):
Preferred stock value
Common stock of $0.01 par value – authorized 300,000,000 shares: issued and outstanding 1,779,275 shares as of June 30, 2026 and 929,597 shares as of June 30, 2025
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity (deficiency)
Total liabilities and stockholders’ equity (deficiency)
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
REVENUES
Collaboration and license
OPERATING EXPENSES
Research and development
General and administrative
Gain on sale of Vyleesi
Gain on purchase commitment
Total operating expenses
Loss from operations
OTHER INCOME (EXPENSE)
Investment income
Foreign currency transaction loss
Interest expense
Total other income, net
NET LOSS
Basic net loss per common share
Diluted net loss per common share
Weighted average number of common shares outstanding used in computing basic net loss per common share
Weighted average number of common shares outstanding used in computing diluted net loss per common share
Balance
Balance, shares
Stock-based compensation
Stock-based compensation, shares
Withholding taxes related to restricted stock units
Withholding taxes related to restricted stock units, shares
Sale of common stock, net of costs
Sale of common stock, net of costs, shares
Warrant exercises
Warrant exercises, shares
Shares released from abeyance
Shares released from abeyance, shares
Net loss
Fractional shares
Fractional shares, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Decrease in right-of-use asset
Unrealized foreign currency transaction loss
Stock-based compensation
Debt cancellation
Gain on sale of Vyleesi
Gain on purchase commitment
Changes in operating assets and liabilities:
Accounts receivable
Other receivables
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Operating lease liabilities
Other liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of Vyleesi
Purchases of property and equipment
Net cash (used in) provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of withholding taxes related to restricted stock units
Proceeds from the sale of common stock and warrants, net
Payment of finance lease obligations
Proceeds from exercise of warrants
Net cash provided by financing activities
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of period
CASH AND CASH EQUIVALENTS, end of period
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Right-of-use assets obtained in exchange for new operating lease obligation
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Accounting Changes and Error Corrections [Abstract]
NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS
Agreement With Boehringer Ingelheim
AGREEMENT WITH BOEHRINGER INGELHEIM
Agreement With Altanispac
AGREEMENT WITH ALTANISPAC
Release And Settlement Agreement
RELEASE AND SETTLEMENT AGREEMENT
Prepaid Expenses And Other Current Assets
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS
Leases
LEASES
Property, Plant, and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET
Payables and Accruals [Abstract]
ACCRUED EXPENSES
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Segment Reporting [Abstract]
SEGMENT INFORMATION
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIENCY)
Income Tax Disclosure [Abstract]
INCOME TAXES
Principles of Consolidation
Use of Estimates
Cash and Cash Equivalents
Fair Value of Financial Instruments
Credit Risk
Property and Equipment
Impairment of Long-Lived Assets
Leases
Revenue Recognition
Research and Development Costs
Accrued Expenses
Stock-Based Compensation
Income Taxes
Net Loss per Common Share
Translation of foreign currencies
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
SCHEDULE OF FAIR VALUE ASSET MEASUREMENT
SCHEDULE OF COMPONENTS OF OPERATING LEASE COST
SCHEDULE OF COMPONENTS OF FINANCING LEASE COST
SCHEDULE OF SUPPLEMENTAL LEASE TERM AND DISCOUNT RATE
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION
SCHEDULE OF MATURITY OF LEASE LIABILITIES
SCHEDULE OF PROPERTY AND EQUIPMENT NET
SCHEDULE OF ACCRUED EXPENSES
Segment Reporting [Table]
Segment Reporting [Line Items]
SCHEDULE OF SEGMENT BASED ON NET LOSS
SCHEDULE OF WARRANT EXERCISES
SCHEDULE OF OUTSTANDING STOCK PURCHASE WARRANTS
SCHEDULE OF STOCK OPTION ACTIVITY
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY
SCHEDULE OF PROVISION FOR INCOME TAXES
SCHEDULE OF DEFERRED TAX ASSETS
SCHEDULE OF EFFECTIVE INCOME TAX RATE
Reverse stock split, description
Accumulated deficit
Net loss
Cash and cash equivalent
Current liabilities
Cash and Cash Equivalent [Table]
Cash and Cash Equivalents [Line Items]
Cash equivalents
Lease liability
Potential number of common shares excluded from diluted EPS
Weighted average vested restricted stock basic
Weighted average vested restricted stock diluted
Weighted average vested restricted stock units
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment, success-based development, regulatory, and commercial milestone payments
Collaboration period
Revenue
Foreign withholding taxes
License revenue
Non-cash debt cancellation
Payable the settlement of certain purchase commitments
Sales based milestone payments
Gain on sale
Gain on purchase commitments
Schedule Of Prepaid Expenses And Other Current Assets
Clinical / regulatory costs
Insurance premiums
Other
Total prepaid expenses and other current assets
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Cash Equivalents - Money market funds
Schedule Of Components Of Operating Lease Cost
Operating lease cost
Variable lease cost
Total operating lease cost
Schedule Of Components Of Financing Lease Cost
Right-of-use asset amortization
Interest expense
Total finance lease cost
Weighted-average remaining lease term (years) operating leases
Weighted-average remaining lease term (years) operating leases
Operating cash flows for operating leases
Operating cash flows for finance leases
Financing cash flows for finance leases
Total measurement of lease liabilities
2027
2028
Less imputed interest
Total
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Property and equipment, gross
Less: Accumulated depreciation and amortization
Clinical / regulatory costs
Other research related expenses
Professional Services
Other
Total accrued expenses
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Contribution amount
Monetary damages sought value
Payment of settlement amount paid
Warrants outstanding amount
Warrants exercise price
Total Revenues
Program spend
Personnel costs
Administrative costs
Gain on Sale of Vyleesi
Gain on Purchase Commitment
Other segment items
Segment net loss
Depreciation
Number of operating segments
Number of reporting segments
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Warrants exercises, shares
Proceeds from warrant exercises
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares of Common Stock
Exercise Price per Share
Latest Termination Date
Number of warrants
Warrants expire date
Warrants expire term
Number of options outstanding, beginning balance
Weighted average exercise price, beginning balance
Weighted average remaining term in years, options outstanding
Number of options, granted
Weighted average exercise price, granted
Number of options, forfeited
Weighted average exercise price, forfeited
Number of options, exercised
Weighted average exercise price, exercised
Number of options, expired
Weighted average exercise price, expired
Number of options, fractional shares
Number of options outstanding, ending balance
Weighted average exercise price, ending balance
Aggregate intrinsic value, options outstanding
Number of options. exercisable
Weighted average exercise price, exercisable
Weighted average remaining term in years, options exercisable
Aggregate intrinsic value, options exercisable
Number of options. expected to vest
Weighted average exercise price, expected to vest
Weighted average remaining term in years, options expected to vest
Aggregate intrinsic value, options expected to vest
Risk-free interest rate
Volatility factor
Dividend yield
Expected option life (years)
Weighted average grant date fair value
Number of RSU, outstanding, beginning balance
Number of RSU, granted
Number of RSU, forfeited
Number of RSU, vested
Number of RSU, expirations
Number of RSU, fractional shares
Number of RSU, outstanding, ending balance
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Description of convertible preferred stock
Conversion price
Warrants to purchase
Preferred stock and warrants combined offering price
Dividend on preferred stock
Gross proceeds from offering
Distributable value of dividend
Shares issued price per share
Distributable value of dividend
Aggregate value
Dividends per share
Shares of common stock
Common stock and warrants combined offering price
Additional shares of common stock
Proceeds from issuance of warrants
Common stock share purchased
Purchase price per share
Offering expenses
Cash fee, percentage
Description of securities purchase agreement
Warrants to purchase shares
Voluntarily contributed stock options number of share
Shares available for grant
Unvested granted shares
Award vesting period description
Stock-based compensation
Unrecognized compensation cost
Weighted average period
Vested shares
Withholding shares
Withholding taxes related to restricted stock units, value
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Total
Net operating loss carryforwards
IRC Section 174
Research and development and AMT tax credits
Stock-based compensation
Foreign tax credits
Basis differences in fixed assets and other
Deferred tax assets, gross
Valuation allowance
Net deferred tax assets
U.S. federal statutory income tax rate
State and local income taxes, net of federal benefit
Tax credits
Non deductible expenses
Changes in valuation allowances
Effective income tax rate
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards
Federal research and development credits
Allowance increased
Prepaid Expenses And Other Current Assets [Text Block]
Prepaid Clinical / regulatory costs.
Insurance premiums.
Tabular disclosure of supplemental lease term and discount rate information related to leases.
Series A Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Stock issued during period value warrant exercises.
Stock issued during period value fractional shares.
Stock issued during period shares warrant exercises.
Stock issued during period shares fractional shares.
Clinical / regulatory costs.
Other research related expenses.
Program spend.
Personnel costs.
Gain on sale of vyleesi.
Segment net income (loss).
Convertible preferred stock description.
Convertible Series D Preferred Stocks [Member]
Warrants to purchase.
Preferred stock and warrants combined offering price.
Convertible Series A Preferred Stocks [Member]
Distributable value of dividend.
Alliance Global Partners [Member]
November 2025 PreFunded Warrants [Member]
November 2025 Series J Warrants [Member]
November 2025 Series K Warrants [Member]
Common stock and warrants combined offering price.
Additional shares of common stock.
Series K Warrants [Member]
May 2025 Series F Warrants [Member]
Investors [Member]
May 2025 Series G Warrants [Member]
May 2025 Series H Warrants [Member]
February 2025 Series E Warrants [Member]
Offering expenses.
Cash fee, percentage.
Description of securities purchase agreement.
Series F Warrants [Member]
Series G Warrants [Member]
Series H Warrants [Member]
Series J Warrants [Member]
Warrant excercises, shares.
Stock Warrants [Member]
December 2024 Existing Warrants [Member]
Series C Warrants [Member]
Series D Warrants [Member]
Schedule of Stock Purchase Warrants [Table Text Block]
October 2022 Placement Agent Warrants [Member]
October 2023 Placement Agent Warrants [Member]
January 2024 Private Warrants [Member]
January 2024 Placement Agent Warrants [Member]
June 2024 Series B Warrants [Member]
December 2024 Series C Warrants [Member]
December 2024 Series D Warrants [Member]
June 2025 Series I Warrants [Member]
November 2025 Placement Agent Warrants [Member]
November 2025 HCW Settlement Warrants [Member]
Number of options, fractional shares.
Time Based Stock Options [Member]
Performance Based Stock Options [Member]
Executive Officers [Member]
Other Employees [Member]
Research Collaboration, License and Patent Assignment Agreement [Member]
Number of RSU, expirations.
Number of RSU, fractional shares.
Altanispac Agreement [Member]
Sales-based milestone payments.
Gain on purchase commitments.
Time Based Restricted Stock Units [Member]
Performance Based Restricted Stock Units [Member]
Deferred tax assets basis differences in fixed assets and other.
Total operating lease cost.
Total measurement of lease liabilities.
Right-of-use assets obtained in exchange for new operating lease obligation.
Gain on purchase commitment.
Sale of common stock net of costs shares.
Sale of common stock net of costs amount.
Schedule of Warrant Exercises [Table Text Block]
Gain on purchase commitment.
Payment of withholding taxes related to restricted stock units.
Contribution of number of share.
2011 Stock Incentive Plan [Member]
Shares available for grant.
Accrued Liabilities [Policy Text Block]
Unrecognized compensation cost.
Agreement With Related Party Company Disclosure [TextBlock]
Agreement With Related Party Companies Disclosure [TextBlock]
The entire disclosure for release and settlement agreement.
State [Member]
Amount of addition to allowance reserve for credit losses arising from purchase of loan and lease portfolios.
Single Reportable Segment [Member]
Withholding taxes related to restricted stock units, shares.
Withholding taxes related to restricted stock units, amount.
June 2025 Private Placement [Member]
Deferred tax assets in IRC section.
Assets, Current
Assets
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Gain (Loss) on Disposition of Other Assets
GainLossOnPurchaseCommitment
Operating Expenses
Operating Income (Loss)
Interest Expense, Nonoperating
Other Nonoperating Income (Expense)
Shares, Outstanding
Stock Issued During Period, Value, Restricted Stock Award, Gross
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax
Share-Based Payment Arrangement, Noncash Expense
Gain (Loss) on Sale of Investments
GainOnPurchaseCommitment
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Other Receivables
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
PaymentsRelatedToTaxWithholdingForRestrictedStockUnits
Finance Lease, Principal Payments
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Lessee, Leases [Policy Text Block]
Prepaid Expense and Other Assets
TotalOperatingLeaseCost
Lease, Cost
Operating Lease, Weighted Average Discount Rate, Percent
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Lessee, Operating Lease, Liability, to be Paid
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
AccruedClinicalRegulatoryCosts
Other Accrued Liabilities, Current
GainOnSaleOfVyleesi
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFractionalShares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
DistributableValueOfDividendPerShare
Employee Benefits and Share-Based Compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance
Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Operating Loss Carryforwards